179 related articles for article (PubMed ID: 37910346)
1. Classification models for predicting the bioactivity of pan-TRK inhibitors and SAR analysis.
Zhao X; Kong Y; Ji Y; Xin X; Chen L; Chen G; Yu C
Mol Divers; 2023 Nov; ():. PubMed ID: 37910346
[TBL] [Abstract][Full Text] [Related]
2. The Use of Pan-Tropomyosin Receptor Kinase Immunohistochemistry as a Screening Tool for the Detection of Neurotrophic Tropomyosin-Related Kinase Fusions: Real-World Data from a National Multicentric Retrospective Study.
Van Bockstal MR; Beniuga G; Craciun L; Creytens D; Dedeurwaerdere F; Delvenne P; Demetter P; De Wiest B; Dewinne K; Habran L; Pauwels P; Theate I; Vander Borght S; Van Der Steen K; Weynand B
Pathobiology; 2022; 89(6):393-406. PubMed ID: 35350025
[TBL] [Abstract][Full Text] [Related]
3. Classification models and SAR analysis on thromboxane A
Ji Y; Li R; Tian Y; Chen G; Yan A
SAR QSAR Environ Res; 2022 Jun; 33(6):429-462. PubMed ID: 35678125
[TBL] [Abstract][Full Text] [Related]
4. Classification of FLT3 inhibitors and SAR analysis by machine learning methods.
Zhao Y; Tian Y; Pang X; Li G; Shi S; Yan A
Mol Divers; 2023 May; ():. PubMed ID: 37142889
[TBL] [Abstract][Full Text] [Related]
5. Classification models and SAR analysis on HDAC1 inhibitors using machine learning methods.
Li R; Tian Y; Yang Z; Ji Y; Ding J; Yan A
Mol Divers; 2023 Jun; 27(3):1037-1051. PubMed ID: 35737257
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in the discovery of tropomyosin receptor kinases TRKs inhibitors: A mini review.
El-Nassan HB; Al-Qadhi MA
Eur J Med Chem; 2023 Oct; 258():115618. PubMed ID: 37413881
[TBL] [Abstract][Full Text] [Related]
7. Classification of HIV-1 Protease Inhibitors by Machine Learning Methods.
Li Y; Tian Y; Qin Z; Yan A
ACS Omega; 2018 Nov; 3(11):15837-15849. PubMed ID: 30556015
[TBL] [Abstract][Full Text] [Related]
8. Timing of NTRK Gene Fusion Testing and Treatment Modifications Following TRK Fusion Status Among US Oncologists Treating TRK Fusion Cancer.
Klink AJ; Kavati A; Gassama AT; Kozlek T; Gajra A; Antoine R
Target Oncol; 2022 May; 17(3):321-328. PubMed ID: 35716252
[TBL] [Abstract][Full Text] [Related]
9. Classification models and SAR analysis on CysLT1 receptor antagonists using machine learning algorithms.
Wang H; Qin Z; Yan A
Mol Divers; 2021 Aug; 25(3):1597-1616. PubMed ID: 33534023
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and Structure-Activity Relationships (SAR) of 3-vinylindazole derivatives as new selective tropomyosin receptor kinases (Trk) inhibitors.
Duan Y; Wang J; Zhu S; Tu ZC; Zhang Z; Chan S; Ding K
Eur J Med Chem; 2020 Oct; 203():112552. PubMed ID: 32702585
[TBL] [Abstract][Full Text] [Related]
11. [Novel targeted therapeutic option in oncology: tropomyosin receptor tyrosine kinase inhibitors].
Kiss E; Pápai Z
Orv Hetil; 2021 Aug; 162(34):1362-1369. PubMed ID: 34428172
[TBL] [Abstract][Full Text] [Related]
12. Computational models for the classification of mPGES-1 inhibitors with fingerprint descriptors.
Xia Z; Yan A
Mol Divers; 2017 Aug; 21(3):661-675. PubMed ID: 28484935
[TBL] [Abstract][Full Text] [Related]
13. Identification and structural analysis of a selective tropomyosin receptor kinase C (TRKC) inhibitor.
Wang Z; Ren J; Jia K; Zhao Y; Liang L; Cheng Z; Huang F; Zhao X; Cheng J; Song S; Sheng T; Wan W; Shu Q; Wu D; Zhang J; Lu T; Chen Y; Ran T; Lu S
Eur J Med Chem; 2022 Nov; 241():114601. PubMed ID: 35872544
[TBL] [Abstract][Full Text] [Related]
14. The Pan-TRK Antibody is a Sensitive and Specific Tool for the Detection of NTRK Fusion Genes.
Bautista-Wong C; Mojica-González Z; Hop-Garcia K; Bornstein Quevedo L
Appl Immunohistochem Mol Morphol; 2023 Apr; 31(4):213-216. PubMed ID: 37017998
[TBL] [Abstract][Full Text] [Related]
15. Rational drug design to explore the structure-activity relationship (SAR) of TRK inhibitors with 2,4-diaminopyrimidine scaffold.
Wu T; Qin Q; Liu N; Zhang C; Lv R; Yin W; Sun Y; Sun Y; Wang R; Zhao D; Cheng M
Eur J Med Chem; 2022 Feb; 230():114096. PubMed ID: 35007864
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and biological evaluation of novel indolin-2-one derivatives as potent second-generation TRKs inhibitors.
Qin Q; Fu Q; Wang X; Lv R; Lu S; Guo Z; Wu T; Sun Y; Sun Y; Liu N; Zhao D; Cheng M
Eur J Med Chem; 2023 May; 253():115291. PubMed ID: 37030091
[TBL] [Abstract][Full Text] [Related]
17. Antibacterial Activity Prediction of Plant Secondary Metabolites Based on a Combined Approach of Graph Clustering and Deep Neural Network.
Karim MB; Kanaya S; Altaf-Ul-Amin M
Mol Inform; 2022 Jul; 41(7):e2100247. PubMed ID: 35014190
[TBL] [Abstract][Full Text] [Related]
18. Tropomyosin receptor kinase inhibitors: a patent update 2009 - 2013.
McCarthy C; Walker E
Expert Opin Ther Pat; 2014 Jul; 24(7):731-44. PubMed ID: 24809946
[TBL] [Abstract][Full Text] [Related]
19. SAR study on inhibitors of GIIA secreted phospholipase A
Zhang S; Li Y; Qin Z; Tu G; Chen G; Yan A
Chem Biol Drug Des; 2019 May; 93(5):666-684. PubMed ID: 30582300
[TBL] [Abstract][Full Text] [Related]
20. Trk receptor tyrosine kinases in metastasis and cancer therapy.
Regua AT; Doheny D; Arrigo A; Lo HW
Discov Med; 2019 Oct; 28(154):195-203. PubMed ID: 31928627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
